Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Donepezil Tds

Research Leaders

5 sponsors active, led by Chattem, Inc.

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Completed4
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT07554664Completed

Central Sensitization, Work-Related Stress, and Musculoskeletal Symptoms in Desk-Based Workers With and Without Migraine

NCT06727825Completed

Evaluation of Grass Pollen Sensitization Among Professionals Exposed or Not Exposed to Flour

NCT06930378Not ApplicableRecruiting

Improvement in Breast Skin Sensibility After Breast Reconstruction: a Comparison of 3 Surgical Techniques

NCT03397862Phase 1Completed

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT01842711Completed

Cumulative Irritation Patch Test

Showing all 5 trials

Research Network

Common Treatments

  • Donepezil Tds1
  • Nerve Suture1
  • Vehicle Tds1

Active Sponsors

  • Chattem, Inc.1
  • Patricia Esther Engels1
  • Centre Hospitalier Intercommunal Creteil1
  • Corium, Inc.1
  • Bozok University1

Top Investigators

Related Conditions

  • Migraine1
  • Work Stress1
  • Diep Flap Breast Reconstruction1
  • Skin Irritation1
  • Asthma1

Activity Timeline